<DOC>
	<DOCNO>NCT01662414</DOCNO>
	<brief_summary>This double-blind , placebo-controlled , Phase IV trial , compare HMS 90® versus placebo ( soy protein ) add-on ( adjuvant ) therapy subject idiopathic Parkinson 's Disease . The principal objective evaluate change biomarkers oxidative stress , plasma amino acid , well improvement clinical symptom brain function</brief_summary>
	<brief_title>Effect Undenatured Cysteine-Rich Whey Protein Isolate ( HMS 90® ) Patients With Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Neurodegenerative Diseases</mesh_term>
	<mesh_term>Central Nervous System Diseases</mesh_term>
	<mesh_term>Parkinsonian Disorders</mesh_term>
	<mesh_term>Basal Ganglia Diseases</mesh_term>
	<criteria>1 . Subjects Idiopathic Parkinson 's Disease 2 . Subjects willing able participate trial provide write , informed consent . 1 . Subjects allergic Whey protein ( HMS 90® ) . 2 . Subjects treat chemotherapy . 3 . Subjects history neurodegenerative disease , e.g. , Alzheimer 's disease . 4 . Subjects history diabetes . 4.5 . Subjects abnormal liver function test</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>